223 related articles for article (PubMed ID: 32242967)
1. Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.
Kim GYG; Burns J; Freyer CW; Hamilton KW; Frey NV; Gill SI; Hexner EO; Luger SM; Mangan JK; Martin ME; McCurdy SR; Perl AE; Porter DL; Schuster MG; Stadtmauer EA; Loren AW
Am J Hematol; 2020 Jul; 95(7):792-798. PubMed ID: 32242967
[TBL] [Abstract][Full Text] [Related]
2. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis?
Pomares H; Arnan M; Sánchez-Ortega I; Sureda A; Duarte RF
Mycoses; 2016 Aug; 59(8):516-9. PubMed ID: 27027972
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for invasive fungal infection in 5-azacytidine treated patients with acute myeloid leukemia and myelodysplastic syndrome.
Tey A; Shaw B; Cardamone L; Shepherd S; Paul E; Rogers B; Shortt J
Eur J Haematol; 2021 Aug; 107(2):181-189. PubMed ID: 33829584
[TBL] [Abstract][Full Text] [Related]
4. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study.
Lien MY; Chou CH; Lin CC; Bai LY; Chiu CF; Yeh SP; Ho MW
PLoS One; 2018; 13(6):e0197851. PubMed ID: 29883443
[TBL] [Abstract][Full Text] [Related]
6. High rate of invasive fungal infections during early cycles of azacitidine for patients with acute myeloid leukemia.
Wang ST; Chou CH; Chen TT; Lin CC; Bai LY; Yeh SP; Ho MW; Lien MY
Front Cell Infect Microbiol; 2022; 12():1012334. PubMed ID: 36530436
[TBL] [Abstract][Full Text] [Related]
7. High incidence of invasive fungal infection during acute myeloid leukemia treatment in a resource-limited country: clinical risk factors and treatment outcomes.
Nganthavee V; Phutthasakda W; Atipas K; Tanpong S; Pungprasert T; Dhirachaikulpanich D; Krithin S; Tanglitanon S; Jutidamronphang W; Owattanapanich W; Chayakulkeeree M; Phikulsod P
Support Care Cancer; 2019 Sep; 27(9):3613-3622. PubMed ID: 31165931
[TBL] [Abstract][Full Text] [Related]
8. The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent.
Ozga M; Huang Y; Blachly JS; Grieselhuber NR; Wall S; Larkin K; Haque T; Walker AR; Bhatnagar B; Behbehani G; Vasu S; Maakaron JE; Lustberg M; Mims AS
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e76-e83. PubMed ID: 32921593
[TBL] [Abstract][Full Text] [Related]
9. Invasive Fungal Infections in Children with Leukemia: Clinical Features and Prognosis.
Sezgin Evim M; Tüfekçi Ö; Baytan B; Ören H; Çelebi S; Ener B; Üstün Elmas K; Yılmaz Ş; Erdem M; Hacımustafaoğlu MK; Güneş AM
Turk J Haematol; 2022 Jun; 39(2):94-102. PubMed ID: 34792308
[TBL] [Abstract][Full Text] [Related]
10. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents.
Kang KW; Lee BH; Jeon MJ; Yu ES; Sik Kim D; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Ther Adv Hematol; 2020; 11():2040620720966882. PubMed ID: 35154623
[TBL] [Abstract][Full Text] [Related]
12. Invasive Fungal Infections in Children With Acute Myeloid Leukemia: A Single-center Experience Over 19 Years.
Avcu G; Karadas N; Goktepe SO; Bal ZS; Metin DY; Polat SH; Aydinok Y; Karapinar DY
J Pediatr Hematol Oncol; 2023 Oct; 45(7):392-397. PubMed ID: 37526370
[TBL] [Abstract][Full Text] [Related]
13. Incidence of invasive fungal infection in acute lymphoblastic and acute myelogenous leukemia in the era of antimold prophylaxis.
Oh SM; Byun JM; Chang E; Kang CK; Shin DY; Koh Y; Hong J; Kim TS; Choe PG; Park WB; Kim NJ; Yoon SS; Kim I; Oh MD
Sci Rep; 2021 Nov; 11(1):22160. PubMed ID: 34773060
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
15. Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002-2018 Empirical/Pre-emptive Approach.
Martino R; Garrido A; Santaliestra M; García-Cadenas I; Novelli S; Saavedra SD; Esquirol A; Granell M; Briones J; Moreno C; Brunet S; Giménez A; Hidalgo A; Sánchez F; Sierra J
Mycopathologia; 2020 Aug; 185(4):639-652. PubMed ID: 32564177
[TBL] [Abstract][Full Text] [Related]
16. Incidence and predisposing factors of infection in patients treated with hypomethylating agents.
Kirkizlar TA; Kirkizlar O; Demirci U; Umut A; Iflazoglu H; Umit EG; Demir AM
Leuk Res; 2023 Apr; 127():107043. PubMed ID: 36801588
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
On S; Rath CG; Lan M; Wu B; Lau KM; Cheung E; Alegria W; Young R; Tan M; Kim C; Phun J; Patel N; Mannis G; Logan AC; Kennedy V; Goodman A; Taplitz RA; Young PA; Wen R; Saunders IM
Br J Haematol; 2022 Apr; 197(1):63-70. PubMed ID: 35174480
[TBL] [Abstract][Full Text] [Related]
18. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
Wasylyshyn A; Linder KA; Castillo CG; Zhou S; Kauffman CA; Miceli MH
Mycopathologia; 2020 Apr; 185(2):299-306. PubMed ID: 31939052
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and Azacitidine.
Zhang A; Johnson T; Abbott D; Phupitakphol T; Gutman JA; Pollyea DA; Koullias Y
Open Forum Infect Dis; 2022 Oct; 9(10):ofac486. PubMed ID: 36225746
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.
Chen EC; Liu Y; Harris CE; Winer ES; Wadleigh M; Lane AA; Vedula RS; Lindsley RC; Copson KM; Charles A; Marty F; Neuberg D; DeAngelo DJ; Stone RM; Luskin MR; Issa NC; Garcia JS
Leuk Lymphoma; 2022 Aug; 63(8):1934-1941. PubMed ID: 35289704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
